INMB
Price
$7.56
Change
-$0.21 (-2.70%)
Updated
Apr 4, 10:45 AM (EDT)
Capitalization
178.63M
26 days until earnings call
WINT
Price
$1.17
Change
-$0.06 (-4.88%)
Updated
Apr 4, 10:40 AM (EDT)
Capitalization
921.69K
Ad is loading...

INMB vs WINT

Header iconINMB vs WINT Comparison
Open Charts INMB vs WINTBanner chart's image
INmune Bio
Price$7.56
Change-$0.21 (-2.70%)
Volume$2.09K
Capitalization178.63M
Windtree Therapeutics
Price$1.17
Change-$0.06 (-4.88%)
Volume$1.12K
Capitalization921.69K
INMB vs WINT Comparison Chart
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WINT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. WINT commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and WINT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (INMB: $7.77 vs. WINT: $1.23)
Brand notoriety: INMB and WINT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 64% vs. WINT: 18%
Market capitalization -- INMB: $178.63M vs. WINT: $921.69K
INMB [@Biotechnology] is valued at $178.63M. WINT’s [@Biotechnology] market capitalization is $921.69K. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileWINT’s FA Score has 1 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • WINT’s FA Score: 1 green, 4 red.
According to our system of comparison, WINT is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 3 TA indicator(s) are bullish while WINT’s TA Score has 5 bullish TA indicator(s).

  • INMB’s TA Score: 3 bullish, 6 bearish.
  • WINT’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, WINT is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а +4.86% price change this week, while WINT (@Biotechnology) price change was -25.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.24%. For the same industry, the average monthly price growth was -15.12%, and the average quarterly price growth was -16.89%.

Reported Earning Dates

INMB is expected to report earnings on Apr 30, 2025.

WINT is expected to report earnings on May 17, 2023.

Industries' Descriptions

@Biotechnology (-9.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INMB($179M) has a higher market cap than WINT($922K). INMB YTD gains are higher at: 66.381 vs. WINT (-92.957). WINT has higher annual earnings (EBITDA): -9.36M vs. INMB (-41.55M). INMB has more cash in the bank: 33.6M vs. WINT (917K). WINT has less debt than INMB: WINT (2.01M) vs INMB (2.91M). INMB has higher revenues than WINT: INMB (42K) vs WINT (0).
INMBWINTINMB / WINT
Capitalization179M922K19,414%
EBITDA-41.55M-9.36M444%
Gain YTD66.381-92.957-71%
P/E RatioN/A0.83-
Revenue42K0-
Total Cash33.6M917K3,664%
Total Debt2.91M2.01M145%
FUNDAMENTALS RATINGS
INMB vs WINT: Fundamental Ratings
INMB
WINT
OUTLOOK RATING
1..100
6326
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
80100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3898
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WINT's Valuation (62) in the Biotechnology industry is somewhat better than the same rating for INMB (98). This means that WINT’s stock grew somewhat faster than INMB’s over the last 12 months.

INMB's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as WINT (100). This means that INMB’s stock grew similarly to WINT’s over the last 12 months.

INMB's SMR Rating (98) in the Biotechnology industry is in the same range as WINT (99). This means that INMB’s stock grew similarly to WINT’s over the last 12 months.

INMB's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for WINT (98). This means that INMB’s stock grew somewhat faster than WINT’s over the last 12 months.

WINT's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for INMB (100). This means that WINT’s stock grew significantly faster than INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBWINT
RSI
ODDS (%)
N/A
Bullish Trend 16 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 16 days ago
69%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 23 days ago
75%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WINT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JCONX26.13N/A
N/A
Janus Henderson Contrarian I
MNHIX24.72N/A
N/A
Manning & Napier Pro-Blend Max Term I
BMCCX16.11N/A
N/A
BlackRock Advantage Large Cap Gr Inv C
RPGIX19.81N/A
N/A
T. Rowe Price Global Industrials
MSHPX13.30N/A
N/A
Morgan Stanley Inst Permanence R6